Replies to post #123505 on Biotech Values

[stockbettor]

I doubt Neulasta is covered by the settlement. Amgen's 10K shows the Neulasta US patent as expiring in Oct 2015. The ratiopharm Neulasta biosimilar is not yet on the market, but I recall a recent report from Teva that the PIII trial for the biosimilar was a success.